Suven Life Sciences' Board approved Q1 financial results.

Suven Life Sciences LimitedSUVEN · Filed with the exchange

Consolidated net loss was ₹127.61 Cr, with total income at ₹11.09 Cr.

Clinical trials advanced with 95% enrollment for SUVN-502 Phase 3 and SUVN-G3031 Phase 3 initiated.

Proceeds from preferential warrants continue to be received.

No comments yet. Be the first.

More from Suven Life Sciences Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.